QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
May 25 2021 - 4:05PM
Business Wire
- KRAS mutations in NSCLC reflect a large underserved patient
population with an unmet need for innovative treatment options
- QIAGEN is developing a tissue-based companion diagnosticin
support of adagrasib, Mirati’s investigational selective KRASG12C
inhibitor
- Program adds to QIAGEN's strong position in KRAS companion
diagnostic testing in NSCLC
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today
announced a global collaboration with Mirati Therapeutics Inc.
(NASDAQ:MRTX) to continue developing a tissue-based KRAS companion
diagnostic to identify patients with cancers that have a KRASG12C
mutation who may benefit from treatment with adagrasib, Mirati’s
investigational, highly selective and potent oral small molecule
inhibitor of KRASG12C.
The agreement initially focuses on a companion diagnostic test
for non-small cell lung cancer (NSCLC), and allows for further
development of tests for other Mirati oncology programs.
The planned companion diagnostic would expand upon QIAGEN’s
therascreen KRAS testing portfolio based on real-time qualitative
PCR for the QIAGEN Rotor-Gene Q MDx instrument, a member of the
modular QIAsymphony family of automation solutions, and builds upon
the Company’s nearly decade of experience in KRAS companion
diagnostic test development and commercialization. QIAGEN and
Mirati have previously partnered for the development of a companion
diagnostic.
“We are pleased Mirati recognizes the success of QIAGEN’s
therascreen platform and continues to partner with us to develop a
tissue-based companion diagnostic to identify patients who may
benefit from adagrasib. QIAGEN’s experience and expertise in
developing diagnostic solutions for Precision Medicine are
well-suited to evaluate patients with non-small cell lung cancer,”
said Jean-Pascal Viola, Senior Vice President and Head of QIAGEN’s
Molecular Diagnostics Business Area. “Our collaboration with Mirati
is a demonstration of QIAGEN’s capabilities as a preferred partner
of pharmaceutical and biotech companies for the creation of
companion diagnostics.”
The therascreen-based companion diagnostic detects KRASG12C, a
genetic mutation that is one of the most common KRAS alterations
linked to cancer. The RAS gene family is the most frequently
mutated oncogene in human cancer, with KRAS being the most
prevalent driver mutation in NSCLC.
QIAGEN is a pioneer in Precision Medicine and the global leader
in collaborations with pharmaceutical and biotechnology companies
to co-develop companion diagnostics, which detect clinically
relevant genetic abnormalities to provide insights that guide
clinical decision-making in diseases such as cancer. QIAGEN has an
unmatched depth and breadth of technologies from next-generation
sequencing (NGS) to polymerase chain reaction (PCR) for companion
diagnostic development. QIAGEN has nine PCR based companion
diagnostics that are FDA approved, including therascreen EGFR for
non-small cell lung cancer, therascreen KRAS for colorectal cancer,
therascreen FGFR for urothelial cancer, therascreen PIK3CA for
breast cancer based on tissue or plasma samples and the therascreen
BRAF kit for colorectal cancer.
Currently, QIAGEN is working under master collaboration
agreements with more than 25 companies to develop and commercialize
companion diagnostic tests for their drug candidates – a deep
pipeline of potential future products to advance Precision Medicine
for the benefit of patients. QIAGEN is partnering with Illumina to
broaden the availability and use of NGS-based in-vitro diagnostic
(IVD) kits, including companion diagnostics, for patient
management.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of March 31,
2020, QIAGEN employed approximately 5,700 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210525005955/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676 pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024